COMMUNIQUÉS West-GlobeNewswire

Kun Peng International Ltd. Announces 1-for-10 Reverse Stock Split
29/05/2026
BEIJING, CHINA, May 29, 2026 (GLOBE NEWSWIRE) -- Kun Peng International Ltd. (OTCQB: KPEA) (the “Company”) announced today that a 1-for-ten (1:10) reverse split of its $0.0001 par value common stock (the “Reverse Stock [...]
Ipsen annonce le lancement d'une opération d’actionnariat salarié
29/05/2026
Ipsen annonce le lancement d'une opération d’actionnariat salarié PARIS, FRANCE, 29 MAI 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY), annonce aujourd’hui le lancement d'une opération d’actionnariat salarié. Cette 5 ème [...]
ALK to present at the Jefferies Global Healthcare Conference in New York
29/05/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to present at the 2026 Jefferies Global Healthcare Conference in New York [...]
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
29/05/2026
Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day Approval advances pediatric diabetes care by introducing a new [...]
Ipsen announces the launch of an Employee Shareholding Plan
29/05/2026
Ipsen announces the launch of an employee shareholding plan PARIS, FRANCE, 29 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the launch of an employee shareholding plan. This fifth transaction in the last [...]
New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma
29/05/2026
MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI ® as early as second line 1 TECVAYLI ® delivered deep and durable responses, with nearly two-thirds of [...]
Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the presentation of results describing Phase 2a efficacy and safety data in patients [...]
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
29/05/2026
Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA [...]
Seer Files ITC Complaint Against Nanomics
29/05/2026
Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations REDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased [...]
Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia
29/05/2026
VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath devices is [...]
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
29/05/2026
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
PICARD MEDICAL, INC. Issues Letter to Shareholders
29/05/2026
TUCSON, Ariz., May 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world’s first and only total [...]
PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
29/05/2026
DELRAY BEACH, Fla., May 29, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the fourth quarter and fiscal [...]
SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
29/05/2026
Mission-critical appointment with extensive public company, multinational, and emerging growth experience as SkyAI advances its agentic finance platform Marks the latest step in the Company’s evolution as it continues [...]
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
29/05/2026
EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026 Company [...]
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its [...]
AEON Clinic Redefines Longevity with Premier NAD+ IV Therapy and Premium IV Drips in Dubai
29/05/2026
DUBAI, United Arab Emirates, May 29, 2026 (GLOBE NEWSWIRE) -- AEON Clinic, Dubai’s premier destination for advanced regenerative medicine and holistic wellness located at Atlantis The Royal, is elevating the city’s [...]
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
29/05/2026
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]

Pages